-$1.53 Earnings Per Share Expected for Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) This Quarter

Equities research analysts predict that Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) will announce ($1.53) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Madrigal Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($1.74) and the highest estimate coming in at ($1.33). Madrigal Pharmaceuticals reported earnings per share of ($0.75) in the same quarter last year, which would indicate a negative year over year growth rate of 104%. The company is expected to issue its next quarterly earnings results on Wednesday, February 26th.

On average, analysts expect that Madrigal Pharmaceuticals will report full year earnings of ($5.10) per share for the current year, with EPS estimates ranging from ($5.39) to ($4.44). For the next financial year, analysts forecast that the firm will report earnings of ($6.79) per share, with EPS estimates ranging from ($8.22) to ($5.22). Zacks’ EPS averages are a mean average based on a survey of research firms that follow Madrigal Pharmaceuticals.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.42) by $0.03. During the same quarter last year, the business posted ($0.56) earnings per share.

Several equities analysts have weighed in on the company. Stifel Nicolaus set a $126.00 target price on Madrigal Pharmaceuticals and gave the company a “hold” rating in a report on Wednesday, August 7th. Citigroup lowered their price objective on Madrigal Pharmaceuticals from $173.00 to $166.00 and set a “buy” rating on the stock in a report on Monday. B. Riley set a $134.00 price objective on Madrigal Pharmaceuticals and gave the company a “buy” rating in a report on Friday, August 9th. Zacks Investment Research downgraded Madrigal Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, October 9th. Finally, BidaskClub upgraded Madrigal Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. One research analyst has rated the stock with a sell rating, two have given a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $160.25.

Several hedge funds have recently modified their holdings of MDGL. Tower Research Capital LLC TRC bought a new stake in shares of Madrigal Pharmaceuticals in the third quarter valued at approximately $41,000. Captrust Financial Advisors bought a new position in Madrigal Pharmaceuticals during the second quarter worth $163,000. Los Angeles Capital Management & Equity Research Inc. acquired a new position in Madrigal Pharmaceuticals during the 2nd quarter valued at $215,000. Metropolitan Life Insurance Co NY raised its stake in Madrigal Pharmaceuticals by 17.9% during the 3rd quarter. Metropolitan Life Insurance Co NY now owns 2,668 shares of the biopharmaceutical company’s stock valued at $230,000 after purchasing an additional 406 shares during the last quarter. Finally, Stanley Laman Group Ltd. acquired a new position in Madrigal Pharmaceuticals during the 2nd quarter valued at $256,000. Institutional investors own 62.15% of the company’s stock.

Shares of NASDAQ:MDGL opened at $113.77 on Friday. The stock has a market capitalization of $1.71 billion, a PE ratio of -51.25 and a beta of 1.15. Madrigal Pharmaceuticals has a 1 year low of $82.31 and a 1 year high of $148.18. The firm has a fifty day moving average price of $98.47 and a 200 day moving average price of $95.70.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia.

Recommended Story: What causes a stock to be most active?

Get a free copy of the Zacks research report on Madrigal Pharmaceuticals (MDGL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Madrigal Pharmaceuticals (NASDAQ:MDGL)

Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit